ANDA 77867, held by Piramal Critical. Sevoflurane.
As of Nov 16, 2026, ANDA 77867 (Sojourn), held by Piramal Critical, was first approved by FDA on May 2, 2007, with 8 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Sevoflurane, USP is indicated for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery. Sevoflurane, USP should be administered only by persons trained in the administration of general anesthesia. Facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment, and circulatory resuscitation must be immediately available. Since level of anesthesia may be altered rapidly, only vaporizers producing predictable concentrations of sevoflurane, USP should be used.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 2, 2007 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sojourn100% · liquid;inhalation | Sevoflurane | Rx |
| Oct 16, 2025 | Supplement 30Labeling · Standard review | Approved | None posted |
| Mar 25, 2020 | Supplement 18Labeling · Standard review | Approved | None posted |
| Sep 16, 2015 | Supplement 12Labeling · Standard review | Approved | None posted |
| Sep 16, 2015 | Supplement 11Labeling · Standard review | Approved | None posted |
| Sep 16, 2015 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jan 31, 2012 | Supplement 8Labeling | Approved | None posted |
| Jan 20, 2012 | Supplement 7Manufacturing | Approved | None posted |
| Mar 16, 2011 | Supplement 4Labeling | Approved | None posted |
| May 2, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters